Cigna has announced it will no longer cover GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in its employee health plan starting July 1, pushing users to pay out-of-pocket. This development underscores the growing trend of employers reducing coverage for expensive medications as prices drop but remain high relative to typical insurance coverage limits. Additionally, a new study shows that long-term use of GLP-1 drugs can significantly reduce the risk of knee replacements, highlighting their potential long-term health benefits and cost savings for both patients and healthcare systems.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
